Cover Image
市場調查報告書

Celltrion, Inc.:開發中產品分析

Celltrion, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 204907
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Celltrion, Inc.:開發中產品分析 Celltrion, Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月30日 內容資訊: 英文 40 Pages
簡介

Celltrion, Inc.是專門研究、開發、製造生技仿製藥及新生技藥品的企業。尤其致力於生技仿製藥部門中的單株抗體(mAb)上的開發。該公司的主要產品有Remsima(類風濕性關節炎·僵直性脊椎炎·潰瘍性大腸炎·克隆氏症·乾癬·乾癬性關節炎的治療藥)和CT-P6(乳癌治療藥),CT-P10(非何杰金氏淋巴瘤·類風濕性關節炎治療藥)等。

本報告提供韓國的生物醫藥品企業──Celltrion, Inc.(Celltrion)的醫藥品研究開發進展相關分析,提供該公司的產品平台結構,及臨床實驗的整體進展,主要開發中產品的簡介與開發情形,以及該公司簡介及最新趨勢等調查。

目錄

Celltrion, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台·檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:合作夥伴產品
    • 合作夥伴產品/並用治療模式

開發中產品的概要

  • 後期階段的開發中產品
    • 登記前產品/並用治療模式
    • PhaseⅢ產品/並用治療模式
  • 臨床實驗階段的開發中產品
    • PhaseⅡ產品/並用治療模式
    • PhaseⅠ產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式
    • 藥物研發階段的產品/並用治療模式

藥物簡介

  • Infliximab的生技仿製藥
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • Trastuzumab的生技仿製藥
  • Rituximab的生技仿製藥
  • CT-P27
  • Adalimumab的生技仿製藥
  • Bevacizumab的生技仿製藥
  • Cetuximab的生技仿製藥
  • CT-P19
  • CT-P26
  • 依那西普(Etanercept)的生技仿製藥
  • paribizumabu的生技仿製藥
  • CT-P24
  • CT-P25

開發平台分析

  • 標的別
  • 各投藥法
  • 分子類別
  • 各作用機制

開發中產品的最新趨勢

暫停開發的產品

企業的聲明

公司所在地及子公司

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08102CDB

Summary

Global Markets Direct's, 'Celltrion, Inc. - Product Pipeline Review - 2016', provides an overview of the Celltrion, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Celltrion, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Celltrion, Inc.
  • The report provides overview of Celltrion, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Celltrion, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Celltrion, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Celltrion, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Celltrion, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Celltrion, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celltrion, Inc. Snapshot
    • Celltrion, Inc. Overview
    • Key Information
    • Key Facts
  • Celltrion, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Celltrion, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Celltrion, Inc. - Pipeline Products Glance
    • Celltrion, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Celltrion, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Celltrion, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Celltrion, Inc. - Drug Profiles
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-27
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetuximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-26
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • palivizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-19
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-24
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-25
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Celltrion, Inc. - Pipeline Analysis
    • Celltrion, Inc. - Pipeline Products by Target
    • Celltrion, Inc. - Pipeline Products by Route of Administration
    • Celltrion, Inc. - Pipeline Products by Molecule Type
    • Celltrion, Inc. - Pipeline Products by Mechanism of Action
  • Celltrion, Inc. - Recent Pipeline Updates
  • Celltrion, Inc. - Dormant Projects
  • Celltrion, Inc. - Company Statement
  • Celltrion, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celltrion, Inc., Key Information
  • Celltrion, Inc., Key Facts
  • Celltrion, Inc. - Pipeline by Indication, 2016
  • Celltrion, Inc. - Pipeline by Stage of Development, 2016
  • Celltrion, Inc. - Monotherapy Products in Pipeline, 2016
  • Celltrion, Inc. - Pre-Registration, 2016
  • Celltrion, Inc. - Phase III, 2016
  • Celltrion, Inc. - Phase II, 2016
  • Celltrion, Inc. - Preclinical, 2016
  • Celltrion, Inc. - Discovery, 2016
  • Celltrion, Inc. - Pipeline by Target, 2016
  • Celltrion, Inc. - Pipeline by Route of Administration, 2016
  • Celltrion, Inc. - Pipeline by Molecule Type, 2016
  • Celltrion, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Celltrion, Inc. - Recent Pipeline Updates, 2016
  • Celltrion, Inc. - Dormant Developmental Projects,2016
  • Celltrion, Inc., Subsidiaries

List of Figures

  • Celltrion, Inc. - Pipeline by Top 10 Indication, 2016
  • Celltrion, Inc. - Pipeline by Stage of Development, 2016
  • Celltrion, Inc. - Monotherapy Products in Pipeline, 2016
  • Celltrion, Inc. - Pipeline by Target, 2016
  • Celltrion, Inc. - Pipeline by Route of Administration, 2016
  • Celltrion, Inc. - Pipeline by Molecule Type, 2016
  • Celltrion, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top